Glibenclamide and Metformin Oral Tablets (Immediate-Release) bulk supplier for pharma manufacturers

Glibenclamide And Metformin Oral Tablets (Immediate-Release) Suppliers & Bulk Manufacturers

Available Forms: Tablets IR

Available Strengths: Glibenclamide 2.5 mg + Metformin 500 mg; Glibenclamide 5 mg + Metformin 500 mg

Reference Brands: Glucovance®,®, Euglucon-M®, Glyburid-M®(EU & US)

Category: Diabetes

This dual formulation combines Glibenclamide, a sulfonylurea that stimulates insulin secretion, and Metformin, which reduces hepatic glucose production and improves insulin sensitivity. The synergistic effect offers better glycemic control in type 2 diabetes, reducing fasting and postprandial glucose levels. It lowers HbA1c effectively and is suitable when monotherapy fails.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Glibenclamide And Metformin Oral Tablets (Immediate-Release)? List it or send an offer →

Product Description: Glibenclamide (Glyburide) + Metformin tablets are approved in several EU countries under fixed-dose combinations and were previously marketed in the USA as Glucovance®. However, due to evolving safety guidelines—especially related to hypoglycemia risk—its availability may vary. In the EU, these combinations are still prescribed under close monitoring for type 2 diabetes management. The European Medicines Agency (EMA) requires risk-benefit evaluation and labeling for renal monitoring. The U.S. FDA formerly approved Glucovance® under NDA 021178. Healthcare buyers and distributors can find these formulations via Pharmatradz.com for compliant global sourcing.

Glibenclamide And Metformin Oral Tablets (Immediate-Release) — third party manufacturing & bulk supply

Glibenclamide And Metformin Oral Tablets (Immediate-Release) is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Glibenclamide And Metformin Oral Tablets (Immediate-Release) is supplied as Tablets IR — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Glibenclamide And Metformin Oral Tablets (Immediate-Release) listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Glibenclamide And Metformin Oral Tablets... →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Glibenclamide and Metformin Oral Tablets (Immediate-Release) is listed as Tablets IR in Glibenclamide 2.5 mg + Metformin 500 mg; Glibenclamide 5 mg + Metformin 500 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Glibenclamide and Metformin Oral Tablets (Immediate-Release) is referenced against Glucovance®,®, Euglucon-M®, Glyburid-M®(EU & US). Reference brands are shown for identification only and remain the property of their respective trademark owners.